NEW YORK (GenomeWeb) – Seegene announced today that it has signed an agreement to develop and supply highly multiplexed real-time PCR reagents and assays for Hologic's Panther Fusion platform.
Under the terms of the collaboration agreement, Seegene will use its dual-priming oligonucleotide (DPO) and tagging oligonucleotide capture and extension (TOCE) technologies, as well as its MuDT technology for simultaneously identifying and quantifying multiple targets in a single fluorescence channel, to develop molecular diagnostics assays for the Fusion platform, which is in development.
Hologic will have worldwide commercialization rights to the assays. Financial terms of the deal were not disclosed.
"Seegene's multiplex reagents will enable simultaneous detection and quantification of various target genes, further broadening the menu of Hologic's Panther Fusion system and strengthening its leadership position in the molecular diagnostic market," Tom West, president of Hologic's diagnostics division, said in a statement.
"Our agreement with Hologic represents another meaningful milestone to Seegene's global expansion initiatives in the molecular diagnostics market," added Seegene Founder and CEO Jong-Yoon Chun.